AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.005

0.000

Volume:4.21M

Turnover:21.05K

Market Cap:23.55M

PE:-0.27

High:0.005

Open:0.005

Low:0.004

Close:0.005

52wk High:0.039

52wk Low:0.004

Shares:4.71B

Float Shares:3.34B

Volume Ratio:0.41

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.019

EPS(LYR):-0.019

ROE:-174.71%

ROA:-45.15%

PB:0.95

PE(LYR):-0.27

Loading ...

Overview Company News Filings

NASDAQ Trade Halt Volatility Trading Pause at 09:42 Am

Radiopharm Completes FDA End-of-Phase 2 Meeting for Rad101 Ahead of Pivotal Brain Metastases Imaging Trial

Radiopharm Theranostics Ltd-Rad Completes Meeting with US FDA for Development of Rad101

THOMSON REUTERS

Radiopharm Theranostics Ltd-Radoc New Class Options Range of Units and Top 20 Holders

THOMSON REUTERS

Radiopharm Theranostics Ltd-Share Purchase Plan Completed

THOMSON REUTERS

Radiopharm Says Interim Phase 2b Rad101 PET Trial Meets Primary Endpoint with 93% MRI Concordance

Press Release: Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of Rad101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Holds General Meeting; All Resolutions Carried by Poll

Radiopharm Reports Positive Phase 1 Imaging Data for Rad301 in Pancreatic Cancer Patients

Radiopharm Theranostics - Significant Tumor Uptake Observed in All Evaluable Pancreatic Cancer Patients

THOMSON REUTERS

Radiopharm Theranostics - Positive Safety and Favorable Biodistribution Observed in All Subjects Dosed with Rad301

THOMSON REUTERS

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of Rad301 in Patients with Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS

Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln

THOMSON REUTERS

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors

THOMSON REUTERS

Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review

Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution

THOMSON REUTERS

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial

THOMSON REUTERS

Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/RAD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.005,"timestamp":1791522720000,"preClose":0.005,"halted":0,"volume":4212449,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4710883000,"eps":-0.01853,"marketStatus":"Market Closed","change":0,"latestTime":"10-09 16:12:00 AEDT","open":0.005,"high":0.005,"low":0.004,"amount":21051,"amplitude":0.2,"askPrice":0.006,"askSize":20034046,"bidPrice":0.005,"bidSize":1414011,"shortable":3,"etf":0,"ttmEps":-0.01853,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791759600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.005,"openAndCloseTimeList":[[1791500400000,1791522000000]],"volumeRatio":0.409624,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.005,"auctionPrice":0.005,"auctionVolume":3863,"auction":3,"marketStatus":"盘后竞价","timestamp":1791522005551}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-45.15%","roe":"-174.71%","lyrEps":-0.01853,"volumeRatio":0.409624,"shares":4710883000,"dividePrice":0,"high":0.005,"amplitude":0.2,"preClose":0.005,"low":0.004,"week52Low":0.004,"pbRate":"0.95","psRate":"1.83","week52High":0.039,"institutionHeld":0,"latestPrice":0.005,"committee":-0.868146,"eps":-0.01853,"divideRate":0,"volume":4212449,"delay":0,"ttmEps":-0.01853,"open":0.005,"prevYearClose":0.025,"prevWeekClose":0.007,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.007,"twentyDayClose":0.008,"sixtyDayClose":0.02,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673088388","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:42 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2673088388","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673088388?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:42","pubTimestamp":1791207769,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:42 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nAQN2MMUNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RAD.AU","RADX","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702738","title":"Radiopharm Completes FDA End-of-Phase 2 Meeting for Rad101 Ahead of Pivotal Brain Metastases Imaging Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702738","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702738?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:11","pubTimestamp":1791202264,"startTime":"0","endTime":"0","summary":"Radiopharm completes FDA end-of-Phase 2 meeting for RAD101 ahead of pivotal brain metastases imaging trialRadiopharm Theranostics completed an FDA end-of-Phase 2 meeting for RAD101, setting the framew","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL8ksxSf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","RAD.AU","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","BK7067","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","LU0314104364.USD","BK4112","BK4585","IE00BKPKM429.USD","BCDF","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","BK4588","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775000","title":"Radiopharm Theranostics Ltd-Rad Completes Meeting with US FDA for Development of Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775000?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:40","pubTimestamp":1791150051,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE4VTBGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668934062","title":"Radiopharm Theranostics Ltd-Radoc New Class Options Range of Units and Top 20 Holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2668934062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668934062?lang=en_us&edition=fundamental","pubTime":"2026-09-17 08:41","pubTimestamp":1789605709,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUE53N4TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668931040","title":"Radiopharm Theranostics Ltd-Share Purchase Plan Completed","url":"https://stock-news.laohu8.com/highlight/detail?id=2668931040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668931040?lang=en_us&edition=fundamental","pubTime":"2026-09-17 08:11","pubTimestamp":1789603913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUE2RCYWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667572665","title":"Radiopharm Says Interim Phase 2b Rad101 PET Trial Meets Primary Endpoint with 93% MRI Concordance","url":"https://stock-news.laohu8.com/highlight/detail?id=2667572665","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667572665?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:05","pubTimestamp":1789387544,"startTime":"0","endTime":"0","summary":"Radiopharm says interim Phase 2b RAD101 PET trial meets primary endpoint with 93% MRI concordanceRadiopharm Theranostics flagged positive interim Phase 2b imaging data for RAD101 in suspected recurren","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL54ZDHc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014039.USD","BK4112","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BCDF","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BQXX3F31.USD","RAD.AU","IE00BQXX3C00.GBP","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK7067","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667037663","title":"Press Release: Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of Rad101 at 2026 Society of Neuro-Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2667037663","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667037663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":"RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpointMeeting with FDA planned on October 1(st) to align on RAD101Phase 3 pivotal trial pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RAD.AU","BK7067","SRS","RADX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666552177","title":"Radiopharm Theranostics Holds General Meeting; All Resolutions Carried by Poll","url":"https://stock-news.laohu8.com/highlight/detail?id=2666552177","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666552177?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:02","pubTimestamp":1789128139,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics holds general meeting; all resolutions carried by pollRadiopharm Theranostics held a general meeting on Friday.Shareholders ratified the prior issue of First Tranche Placement ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL9bVlB2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666551587","title":"Radiopharm Reports Positive Phase 1 Imaging Data for Rad301 in Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551587","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:04","pubTimestamp":1788951890,"startTime":"0","endTime":"0","summary":"Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer patientsRadiopharm Theranostics reported positive Phase 1 imaging results for RAD301 in healthy volunteers, patients wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL79Nw0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","LU2095319765.USD","SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","BCDF","BK7067","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","LU0314104364.USD","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","IE00BQXX3F31.USD","BK4585","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666958797","title":"Radiopharm Theranostics - Significant Tumor Uptake Observed in All Evaluable Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666958797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666958797?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587975","title":"Radiopharm Theranostics - Positive Safety and Favorable Biodistribution Observed in All Subjects Dosed with Rad301","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587975?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666090582","title":"Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of Rad301 in Patients with Pancreatic Ductal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2666090582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666090582?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051887","title":"Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051887?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051884","title":"Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051884?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051881","title":"Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051881?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718764","title":"Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718764?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:00","pubTimestamp":1787742001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA86WLSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286639","title":"Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286639","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286639?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:03","pubTimestamp":1787223813,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics advances 177Lu-RAD202 Phase 1 HEAT trial to 180 mCi dose cohort after DSMC reviewRadiopharm Theranostics moved its Phase 1 HEAT trial of 177Lu-RAD202 into Cohort 4 following a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL8L5MBh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","IE00BGHQF748.EUR","BK7067","SG9999014005.SGD","NDAQ","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","LU2210150020.SGD","BK4585","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660728687","title":"Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2660728687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660728687?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332286","title":"Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332286?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286382","title":"Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286382?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}